Cardinal Health reported fourth-quarter fiscal 2026 adjusted earnings per share of $2.91, beating the Zacks Consensus Estimate by 20.3% and up 40% year over year, while quarterly revenues rose 6% to $63.67 billion but missed the consensus estimate by 2.9%. GAAP earnings per share in the quarter was $1.70 compared with $1.00 a year earlier, and full-year fiscal 2026 adjusted EPS was $11.26, up 37% from fiscal 2025, with full-year revenues of $254.25 billion, up 14%. Within the quarter, Pharmaceutical and Specialty Solutions revenues rose 6% to $58.85 billion with segment profit of $645 million, up 21%, while Global Medical Products and Distribution revenues fell 2% to $3.13 billion even as segment profit rose to $150 million from $70 million, and the Other segment, comprising Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics, posted revenues of $1.72 billion, up 7%, with profit of $183 million, up 14%. Cardinal Health raised its fiscal 2027 earnings guidance to adjusted earnings per share of $12.40 to $12.60, implying growth of 13% to 15% from adjusted fiscal 2026 results excluding the IEEPA tariff refund benefit, and guided Pharmaceutical and Specialty Solutions revenue growth of 3% to 5% with segment profit up 8% to 11%, Global Medical Products and Distribution revenue growth of 2% to 4% with segment profit of $200 million to $220 million, and Other segment revenue growth of 11% to 13% with segment profit up 15% to 18%.
Cardinal Health IncCardinal Health beat Q4 EPS estimates and raised fiscal 2027 adjusted EPS guidance to $12.40-$12.60.
McKesson Corporation